HC Wainwright Issues Optimistic Estimate for MBOT Earnings

Microbot Medical Inc. (NASDAQ:MBOT) – Analysts at HC Wainwright upped their Q3 2025 EPS estimates for Microbot Medical in a research report issued to clients and investors on Wednesday, August 20th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their prior forecast of ($0.08). The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.25) EPS.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02).

Separately, Wall Street Zen upgraded shares of Microbot Medical from a “sell” rating to a “hold” rating in a research note on Saturday, June 14th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $9.00.

Microbot Medical Trading Up 8.1%

Shares of MBOT stock opened at $3.85 on Friday. Microbot Medical has a 12 month low of $0.82 and a 12 month high of $3.94. The stock has a market cap of $175.37 million, a PE ratio of -6.64 and a beta of 1.15. The company’s fifty day moving average price is $2.72 and its 200-day moving average price is $2.30.

Institutional Investors Weigh In On Microbot Medical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new stake in Microbot Medical in the 4th quarter worth approximately $118,000. Geode Capital Management LLC increased its holdings in Microbot Medical by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 10,442 shares in the last quarter. Virtu Financial LLC purchased a new stake in Microbot Medical in the 1st quarter worth approximately $42,000. XTX Topco Ltd purchased a new stake in Microbot Medical in the 2nd quarter worth approximately $43,000. Finally, American Century Companies Inc. purchased a new stake in Microbot Medical in the 2nd quarter worth approximately $32,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.